Vir Biotechnology stock gains on conference participation and 52-week high

Published on 09/02/2026 at 06:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vir Biotechnology stock has climbed strongly in recent weeks, with investors now watching its upcoming appearance at a major healthcare conference and the stock’s move to a new 52-week high.

VIR, US92764N1028, Illustration mit AI erstellt.

Vir Biotechnology stock (ISIN US92764N1028) has extended its recent recovery, with the company’s shares trading at 11.70 USD as of September 1, 2026 and standing just above a newly marked 52-week high of 11.66 USD according to market data compiled by Investing.com.

Stock near 52-week high after strong run

According to data from Investing.com dated September 1, 2026, Vir Biotechnology stock has reached a 52-week high at 11.66 USD and was recently quoted at 11.70 USD.

The same overview puts the company’s market capitalization at approximately 1.97 billion USD as of September 1, 2026, reflecting how the recovery in the share price has lifted the company’s equity value.

Investing.com also highlights that Vir Biotechnology stock has delivered a year-to-date return of about 81 percent in 2026, underscoring the scale of the turnaround in the share price compared with the levels seen at the beginning of the year.

Conference appearance keeps investors focused

A separate market summary compiled by StockTitan lists Vir Biotechnology among stocks gaining on news in early September 2026.

In that overview, Vir Biotechnology is recorded with a move of about plus 6.31 percent against the close of the August 31, 2026 session and a market capitalization figure around 1.85 billion USD today, indicating that the stock’s positive momentum has continued into the new month.

StockTitan also notes that Vir Biotechnology plans to participate in the Morgan Stanley 24th Annual Global Healthcare Conference, a regular gathering for institutional investors and healthcare companies, which provides an additional point of interest for shareholders as management presents its strategy and pipeline.

Go deeper

More data and investor information on Vir Biotechnology

Investors can find additional background on Vir Biotechnology stock and its latest filings and presentations via the AD HOC NEWS topic overview and the company’s own investor relations pages.

Vir Biotechnology overview on AD HOC NEWS Investor Relations

Antiviral focus and pipeline context

Vir Biotechnology focuses on developing therapies for serious infectious diseases, with its research platform centered on the immune system’s ability to prevent and treat viral infections.

One of its well known development areas is the search for new treatments and preventative approaches against respiratory viruses, hepatitis and other high impact infectious diseases, which places the company among specialized biotech peers in the United States.

For investors, presentations at conferences such as the Morgan Stanley 24th Annual Global Healthcare Conference are often used to update the market on progress in these programs, including clinical trial timelines, regulatory milestones and potential commercial opportunities.

Stock valuation and investor perspective

With Vir Biotechnology stock trading close to its 52-week high of 11.66 USD and a recent quote at 11.70 USD as of September 1, 2026, the current price sits in the upper part of the observed range reported by Investing.com.

Combined with a year-to-date gain of about 81 percent in 2026 and a market capitalization near the 2 billion USD mark, the numbers illustrate how the market has reassessed the company’s prospects over the course of the year.

For investors, the next catalysts are likely to include further conference appearances, any updates on clinical data and regulatory interactions, and the next set of quarterly figures once reported.